The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite statin treatment, hyperlipidemia remains problematic after cardiac transplantation and is associated with the development of cardiac allograft vasculopathy. The cholesterol absorption inhibitor ezetimibe may offer a viable option for add on therapy; however, questions have been raised regarding the safety of this during concomitant cyclosporin treatment. METHODS: This is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyclosporin. Sixty-eight cardiac transplant patients were randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition to usual treatments. Fasting blood tests were performed at regular time intervals during the study. RESULTS: Fifty-nine patients completed the study. At 6 months, ezetimibe had reduced total cholesterol by 18% (5.4+/-1.1 to 4.4+/-0.7 mmol/L, P<0.001), low-density lipoprotein cholesterol by 26% (3.0+/-1.0 to 2.1+/-0.7 mmol/L, P<0.001), and triglycerides by 13.5% (2.3+/-1.3 to 1.8+/-0.9 mmol/L, P=0.02). Tolerability was excellent with no patients experiencing predefined safety endpoints. An equal number of patients withdrew consent from each arm of the study because of perceived side effects. Specific analysis confirmed ezetimibe had no significant effect on cyclosporin levels. CONCLUSION: We conclude that ezetimibe is both efficacious and tolerable in cardiac transplant recipients taking cyclosporin. It can be safely considered as add on therapy in patients taking statins (or as monotherapy) to further reduce low-density lipoprotein levels, which may in turn reduce the risk of cardiac allograft vasculopathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients who underwent transcatheter aortic valve replacement, statin therapy was associated with improved outcomes in a small observational study [486].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [486]
Citations
Cites
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301 · cited 3×
“Indeed, over a chronic time setting ( 5 years from transplant) CAV represents one of the most commonest causes for death in these patients (2).”
BackgroundSimvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241 · cited 1×
“The benefit of LDL lowering by ezetimibe has recently been brought under question following the results of the ENHANCE study (20).”
Cardiac Allograft Vasculopathy: Recent Developments
Schmauss, D., & Weis, M. (2008) · Circulation · doi:10.1161/circulationaha.107.711911 · Cited by 587
Taylor, D. O., Edwards, L. B., Boucek, M. M., Trulock, E. P., Aurora, P., Christie, J., Dobbels, F., Rahmel, A. O., Keck, B. M., & Hertz, M. I. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.06.004 · Cited by 505
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Dujovne, C. A., Ettinger, M. P., McNeer, J. F., Lipka, L. J., LeBeaut, A. P., Suresh, R., Yang, B. O., & Veltri, E. P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02798-4 · Cited by 391
Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels
Ballantyne, C. M. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430010065032 · Cited by 281
Pearson, T. A., Denke, M. A., McBride, P. E., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.5.587 · Cited by 247
Simvastatin Initiated Early After Heart Transplantation: 8-Year Prospective Experience
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Krobot, K., Steinbeck, G., Seidel, D., & Reichart, B. (2003) · Circulation · doi:10.1161/01.cir.0000043241.32523.ee · Cited by 247
Statin myopathy: Incidence, risk factors, and pathophysiology
Sewright, K. A., Clarkson, P. M., & Thompson, P. D. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0050-3 · Cited by 101
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“Some recent guidelines recommend non-HDL-C as a better risk indicator than LDL-C.”
BackgroundInfluential
Metadata
- Authors
- Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K. H., Baynes, A. C., O’Neill, N., Fildes, J. E., Yonan, N., & Williams, S. G.
- Affiliations
- Wythenshawe Hospital (GB)
- Corresponding author
- Shaw, Steven M.
- ORCID
- Venue
- Transplantation
- Published
- 2009-03-15
- Volume
- 87
- Issue
- 5
- Pages
- 771-775
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2142988574
- Cited by
- 31
- References
- 20
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2022: 1 · 2020: 2 · 2019: 4 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ezetimibe, cyclosporine, heart transplantation, hyperlipidemia, cholesterol absorption inhibitors, LDL cholesterol lowering, triglycerides, drug-drug interactions, cardiac allograft vasculopathy, tolerability
- MeSH terms
- Ezetimibe, Adult, Aged, Anticholesteremic Agents, Azetidines, Cholesterol, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Lipoproteins, LDL, Male, Middle Aged, Placebos, Safety, Heart Transplantation, Cyclosporine, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin. https://app.cochat.ai/papers/10.1097/tp.0b013e318198d7d0
- The paper
- Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K. H., Baynes, A. C., O’Neill, N., Fildes, J. E., Yonan, N., & Williams, S. G. (2009). The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin. Transplantation. https://doi.org/10.1097/tp.0b013e318198d7d0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.